GlassScriptPhysician profile
Melody Fitch
NPI 1255695219
$1,407.75
in general payments reported to CMS, 2019-2025
14 companies · $646 in 2025
The $646 reported for 2025 was more than what 83% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $125 · 2022: $64.49 · 2023: $293 · 2024: $279 · 2025: $646.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,218.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,218.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rxsight INC | $323.69 | 2023-2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Injector Cartridge |
| Tarsus Pharmaceuticals, INC. | $243.76 | 2024-2025 | Xdemvy |
| Sun Pharmaceutical Industries INC. | $165.51 | 2023-2025 | Cequa |
| Aerie Pharmaceuticals, INC. | $125.00 | 2021 | |
| Oyster Point Pharma, INC. | $111.77 | 2022-2024 | Tyrvaya |
| Abbvie INC. | $87.90 | 2024-2025 | |
| Bausch & Lomb Americas INC. | $77.86 | 2023-2025 | Vyzulta, Miebo |
| Alcon Vision LLC | $68.99 | 2022-2025 | Rocklatan, Eysuvis |
| Harrow Eye, LLC | $60.51 | 2025 | Vevye |
| Thea Pharma INC. | $41.15 | 2022-2025 | Iyuzeh |
| Amgen INC. | $34.19 | 2025 | |
| Eyevance Pharmaceuticals LLC | $25.57 | 2023 | Flarex |
| Dompe US, INC. | $23.61 | 2024 | Oxervate |
| Biotissue Holdings INC. | $18.24 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melody Fitch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.